Browsing Category
45134 posts
Yingli Pharma Announces Successful End-of-Phase 2 Meeting with FDA and Clearance of Global Multi-center Phase 3 Registration Study Design of Linperlisib for the Treatment of Relapsed and/or Refractory Peripheral T-cell Lymphoma
SAN FRANCISCO, April 1, 2025 /PRNewswire/ — Shanghai Yingli Pharmaceutical Co., Ltd.…



